Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.36 USD
−82.44 M USD
0.00 USD
42.93 M
About Black Diamond Therapeutics, Inc.
Sector
Industry
CEO
Mark A. Velleca
Website
Headquarters
Cambridge
Founded
2014
FIGI
BBG00MS4Y0W9
Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BDTX is 2.64 USD — it has increased by 3.13% in the past 24 hours. Watch Black Diamond Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Black Diamond Therapeutics, Inc. stocks are traded under the ticker BDTX.
BDTX stock has risen by 10.00% compared to the previous week, the month change is a −7.69% fall, over the last year Black Diamond Therapeutics, Inc. has showed a −4.00% decrease.
We've gathered analysts' opinions on Black Diamond Therapeutics, Inc. future price: according to them, BDTX price has a max estimate of 20.00 USD and a min estimate of 9.00 USD. Watch BDTX chart and read a more detailed Black Diamond Therapeutics, Inc. stock forecast: see what analysts think of Black Diamond Therapeutics, Inc. and suggest that you do with its stocks.
BDTX reached its all-time high on Jun 3, 2020 with the price of 46.25 USD, and its all-time low was 1.18 USD and was reached on Oct 17, 2022. View more price dynamics on BDTX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BDTX stock is 6.36% volatile and has beta coefficient of 2.43. Track Black Diamond Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Black Diamond Therapeutics, Inc. there?
Today Black Diamond Therapeutics, Inc. has the market capitalization of 144.86 M, it has increased by 7.23% over the last week.
Yes, you can track Black Diamond Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Black Diamond Therapeutics, Inc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
BDTX earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.37 USD resulting in a 25.00% surprise. The estimated earnings for the next quarter are −0.31 USD per share. See more details about Black Diamond Therapeutics, Inc. earnings.
Black Diamond Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
BDTX net income for the last quarter is −15.56 M USD, while the quarter before that showed −19.91 M USD of net income which accounts for 21.86% change. Track more Black Diamond Therapeutics, Inc. financial stats to get the full picture.
No, BDTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 17, 2024, the company has 54.00 employees. See our rating of the largest employees — is Black Diamond Therapeutics, Inc. on this list?
Like other stocks, BDTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Black Diamond Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Black Diamond Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Black Diamond Therapeutics, Inc. stock shows the sell signal. See more of Black Diamond Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.